Sponsor a session on the program at AusBiotech 2018

 

Align your brand with a relevant session

$7,600 for members | $9,900 for nonmembers

Inclusions:

Opportunity to provide a chair in one of the below sessions which includes a conference day pass 
One (1) full conference registration
Opportunity to provide printed material to delegates during the session
Logo included on the holding slide during the nominated session and in the program and on the event website
Opportunity to provide a gobo for logo projection during the during the nominated session
Acknowledgement in electronic and printed materials leading up to and during AusBiotech 2018
Acknowledgement within pre and post marketing activities 

* approval is required from the program committee regarding suitability

 

Topics

Global life science investing and industry update
John Carroll, Editor in Chief, Endpoints 

 

Keeping the balance in your clinical portfolio - prioritisation versus doing it all
Dr Charmaine Gittleson, Chief Medical Officer, CSL Limited

 

Big pharma panel:

Liz Chatwin, Country President, AstraZeneca Aust/NZ

Ben Thorner, Senior Vice President & Head of Business Development & Licensing, Merck Research Laboratories

Kathy Connell, Senior Director, New Ventures ANZ, Johnson & Johnson Innovation

Dr Anand Gautam, Senior Director & Head, External Science & Innovation, Australia, New Zealand & Southeast Asia, Pfizer

Dr Stephen Hitchcock, Head of Research, Takeda Pharmaceutical 

 

From bench to bedside: GPCR drug discovery

Despite significant market size, over 80% of GPCR targets are yet to be effectively exploited. This session will explore GPCRs in a number of therapeutic areas

Samantha Cobb, Chief Executive Officer, AdAlta

Assoc Prof Kevin Pfleger, Chief Scientific Adviser, Dimerix Ltd

Dr Chris Langmead, Head, Servier Drug Discovery Program, Monash Institute of Pharmaceutical Services

Dr John Flygare, Senior Principal Scientist, Merck

 

Investor session panel: 

Lawrence Gozlan, Portfolio Manager, Scientia Capital

John Carroll, Editor in Chief, Endpoint

James Ieong, Head of IC – Chairman, Pagoda Investment

Dr Sam Bakri, Global Entrepreneurs Programme UK 

 

Update on the Innovation, Science and Research System Review/Strategic Plan
Dr Charlie Day, Chief Executive Officer, Office of Innovation & Science Australia

 

Creating investor value - recent Australian public company exits

Rob Daniels, Chief Executive Officer, Elastagen

Dr Tony Keating, CEO, ResApp

David Blake, Founder, Bioshares 

Stuart Roberts, Founder & Senior Analyst, NDF Research